The hyperkinetic child syndrome and brain monoamines: pharmacology and therapeutic implications.
Decreased catecholaminergic activity within the central nervous system has been associated with altered arousal, attention, learning, and kinetic function in animals and humans. The hyperkinetic child syndrome (HCS) involves dysfunction in all these spheres and may thus reflect diminished catecholamine activity, particularly as related to brain dopamine. Accordingly, the efficacy of catecholaminergic agents in treating the HCS is a predictable rather than a paradoxical effect of these agents. Sufficient evidence is now available to strongly implicate catecholamine hypoactivity in the pathopharmacology of the HCS.
D000818:Animals; D001143:Arousal / Q000187:drug effects; D001288:Attention / Q000502:physiology; D001921:Brain / Q000378:metabolism*; D002648:Child; D003913:Dextroamphetamine / Q000494:pharmacology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D006948:Hyperkinesis / Q000378:metabolism* / Q000652:urine; D007099:Imipramine / Q000494:pharmacology; D008734:Methoxyhydroxyphenylglycol / Q000652:urine; D008774:Methylphenidate / Q000494:pharmacology; D010389:Pemoline / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000187:drug effects
D008774:Methylphenidate; D008734:Methoxyhydroxyphenylglycol; D010389:Pemoline; D007099:Imipramine; D003913:Dextroamphetamine; D004298:Dopamine